Key Takeaways
(Bloomberg) -- Sino Biopharmaceutical’s subsidiary secured its second Chinese approval for the innovative breast cancer drug culmerciclib, now cleared for first-line use in patients with the most common subtype of the disease.
"This is the second indication approved for marketing of culmerciclib," the company announced in a statement Tuesday.
The approval from China's National Medical Products Administration (NMPA) covers the CDK2/4/6 inhibitor, in combination with fulvestrant, for initial endocrine therapy. The decision was based on the Phase III CULMINATE-2 trial, which showed the combination reduced the risk of disease progression or death by 44% compared to the control group in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The expanded label strengthens Sino Biopharmaceutical's position in China's competitive oncology market and offers a new initial therapy option with a manageable safety profile for the nation's most prevalent form of breast cancer.
The drug, a national Category 1 innovative drug, was developed by the company's subsidiary, Chia Tai Tianqing Pharmaceutical Group. The new approval adds to culmerciclib's existing indication for later-line settings. The CULMINATE-2 study highlighted the drug's manageable safety, with relatively low rates of high-grade myelosuppression and few treatment discontinuations.
The approval positions culmerciclib as a key domestic competitor in China's growing CDK inhibitor market. Investors will watch for initial sales data in the coming quarters to gauge its uptake against established rivals.
This article is for informational purposes only and does not constitute investment advice.
